Developing a vaccine to protect against avian influenza A virus
Protection and Immunity after Polyanhydride Nanoparticle Vaccination against Avian Influenza A Virus
This study is testing a new vaccine made with tiny particles to help protect birds from the H5N2 strain of avian flu by boosting their immune system, especially in their lungs and noses, before looking into how it might work for humans.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project ID | NIH-10975960 on NIH RePORTER |
What this research studies
This research focuses on creating a novel vaccine using polyanhydride nanoparticles to provide immunity against the avian influenza A virus, particularly the H5N2 subtype. The approach aims to induce both systemic and local immune responses, specifically targeting memory T and B cells in the lungs and nasal mucosa, which are crucial for long-term protection. By enhancing the immune response in these areas, the researchers hope to improve the effectiveness of the vaccine against various strains of the influenza virus. The study will involve evaluating the vaccine's ability to generate robust immune responses in animal models before considering human applications.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals at high risk for influenza infections, such as those with compromised immune systems or those in close contact with birds.
Not a fit: Patients who are not at risk for avian influenza or those who have already been vaccinated against seasonal influenza may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective vaccine that provides better protection against avian influenza, potentially reducing the risk of severe illness and death.
How similar studies have performed: Other research has shown promise in developing vaccines that induce local immune responses, suggesting that this approach could be effective.
Where this research is happening
Iowa City, United States
- University of Iowa — Iowa City, United States (Active)
Researchers
- Principal investigator: Legge, Kevin L — University of Iowa
- Study coordinator: Legge, Kevin L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.